Wilson Sonsini advised RxSight, and Davis Polk advised the sole bookrunning manager in the offering. RxSight, Inc. announced a $50 million SEC-registered follow-on offering of 4,000,000...
RxSight’s $50 Million Common Shares Offering
ADC Therapeutics’s $60 Million Common Shares Secondary Offering
Davis Polk and Homburger advised ADC Therapeutics, while Cooley and Lenz & Staehelin advised the underwriter. ADC Therapeutics SA announced a registered secondary offering of 12,000,000...
TD SYNNEX’s $502 Million Secondary Offering
Pillsbury Winthrop advised TD SYNNEX, Paul Weiss advised the selling stockholders, and Davis Polk advised the lead book-running managers. TD SYNNEX Corporation announced the approximately $502...
Priveterra Acquisition’s Merger With AEON Biopharma
Davis Polk & Wardwell advised Priveterra Acquisition Corp., while Latham & Watkins advised AEON on the deal. Priveterra Acquisition Corp. announced its acquisition of AEON Biopharma...
Snail’s $15 Million Initial Public Offering
Davis Polk advised Snail on the deal. Snail, Inc. executed its SEC-registered initial public offering of 3,000,000 shares of Class A common stock for total gross...
Tenaya Therapeutics’ $75 Million Shares Offering
Wilson Sonsini Goodrich & Rosati advised Tenaya on the deal, while Davis Polk advised the joint book-running managers and representatives of the several underwriters. Clinical stage...
Nayax’s Direct Listing on Nasdaq
Davis Polk and Herzog advised Nayax on the transaction. Nayax Ltd. announced the direct listing of its ordinary shares on Nasdaq in the United States and the...
RxSight’s $50 Million At-The-Market Offering
Davis Polk advised the sales agent in the offering. RxSight, Inc. announced its shares of common stock for up to an aggregate amount of $50 million....
Infinera’s $373.75 Million Convertible Senior Notes Offering
Davis Polk advised Jefferies, the sole book-running manager, in the offering. Infinera Corporation executed its offering of $373.75 million aggregate principal amount of 3.75% convertible senior...
Legend Biotech’s $403 Million Shares Offering
Davis Polk advised the underwriters in the offering while Jones Day advised GenScript Biotech Corporation. Legend Biotech Corporation executed its $403 million SEC-registered follow-on offering of 9,361,000...
GE Gas Power’s Acquisition of Nexus Controls
Davis Polk advised Baker Hughes on the deal. Baker Hughes executed the sale of Nexus Controls to GE’s Gas Power business. Financial terms of the transaction...
GSK’s $3.3 Billion Acquisition of Affinivax
Davis Polk advised GSK plc on the deal while Gunderson Dettmer represented Affinivax. GSK plc announced its acquisition of Affinivax, Inc. for a $2.1 billion upfront...